Rep. Gilbert Ray Cisneros, Jr. Sells Medpace Holdings, Inc. (NASDAQ:MEDP) Stock

Posted by James Quigley on Nov 24th, 2025

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Medpace Holdings, Inc. (NASDAQ:MEDP). In a filing disclosed on November 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medpace stock on October 9th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of CommVault Systems (NASDAQ:CVLT) on 11/3/2025.
Sold $1,001 – $15,000 in shares of The Descartes Systems Group (NASDAQ:DSGX) on 11/3/2025.
Purchased $1,001 – $15,000 in shares of Cohen & Steers (NYSE:CNS) on 10/30/2025.
Purchased $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 10/30/2025.
Sold $1,001 – $15,000 in shares of UFP Industries (NASDAQ:UFPI) on 10/30/2025.
Purchased $1,001 – $15,000 in shares of Enerpac Tool Group (NYSE:EPAC) on 10/30/2025.
Sold $1,001 – $15,000 in shares of Sterling Infrastructure (NASDAQ:STRL) on 10/30/2025.
Purchased $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 10/21/2025.
Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 10/21/2025.
Purchased $1,001 – $15,000 in shares of Iberdrola (OTCMKTS:IBDSF) on 10/21/2025.

Medpace Trading Up 3.1%

Shares of NASDAQ:MEDP traded up $18.11 during trading on Monday, hitting $609.93. 242,332 shares of the company’s stock were exchanged, compared to its average volume of 411,407. The firm has a market cap of $17.18 billion, a P/E ratio of 42.65, a PEG ratio of 2.67 and a beta of 1.42. The firm has a 50-day moving average price of $549.46 and a two-hundred day moving average price of $434.67. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $625.00.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on MEDP shares. Rothschild & Co Redburn lowered Medpace from a “buy” rating to a “neutral” rating and boosted their price target for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. TD Cowen boosted their price target on shares of Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research report on Friday, October 24th. Finally, Truist Financial set a $555.00 target price on Medpace in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $487.18.

View Our Latest Report on Medpace

Hedge Funds Weigh In On Medpace

Several hedge funds and other institutional investors have recently modified their holdings of MEDP. Quent Capital LLC acquired a new stake in Medpace in the third quarter valued at about $25,000. Optiver Holding B.V. bought a new position in shares of Medpace in the third quarter worth about $27,000. Geneos Wealth Management Inc. boosted its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Brooklyn Investment Group increased its holdings in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after purchasing an additional 71 shares in the last quarter. Finally, Quarry LP bought a new position in shares of Medpace during the 3rd quarter worth about $35,000. Institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other news, Director Fred B. Davenport, Jr. sold 5,972 shares of the company’s stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $581.88, for a total value of $3,474,987.36. Following the completion of the transaction, the director directly owned 3,498 shares of the company’s stock, valued at $2,035,416.24. This represents a 63.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Robert O. Kraft sold 6,472 shares of the business’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $591.85, for a total transaction of $3,830,453.20. Following the completion of the transaction, the director directly owned 833 shares in the company, valued at $493,011.05. This trade represents a 88.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 201,308 shares of company stock worth $114,534,479. Company insiders own 20.30% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Medpace Company Profile

(Get Free Report)

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.